Roger Eacock

Ottawa biotech firm says it is restructuring in the wake of a “higher-than-expected level of inconclusive results” from its rapid COVID-19 testing device.
Ottawa biotech firm predicts revenues will top $200 million this year ​– and only rise from there.
Ottawa company says it plans to begin shipping the device “immediately” to federal and provincial governments as well as commercial customers.
After facing months of delays, Ottawa biotech firm is hoping its rapid testing device is poised to clear the final hurdle before it can go to market.
Chief executive Roger Eacock says rapid COVID-19 tests are poised to make local biotech company a force on the 'international stage.'